Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Hansa Biopharma taps Cradle's AI to design next-generation autoimmune therapeutics
Hansa Biopharma, the Swedish company behind the immunoglobulin G (IgG)-cleaving enzyme imlifidase, will use the AI protein-engineering platform from Dutch-Swiss firm Cradle to design its next generation of autoimmune drug candidates, the companies announced Oct. 1. Hansa’s scientists will combine Cradle’s tools with Hansa’s existing experimental data, disease knowledge and protein-engineering expertise. “We’re not building… The post Hansa Biopha…
Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
Hansa is deploying Cradle’s end-to-end platform to develop novel immunomodulatory therapies in autoimmune disease. LUND, Sweden and AMSTERDAM, The Netherlands, October 1, 2026 – Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a partnership with Cradle, which builds the leading AI-driven protein design and […]
Specialist pharmaceutical company Hansa Biopharma has entered into a collaboration with Cradle to develop AI-driven protein design and protein engineering. The aim is to develop new immunomodulatory treatments for autoimmune diseases, according to a press release.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
